Advancing Radiomodulator-Enhanced Radiation Therapy for Superior Tumor Control and Reduced Late Toxicity

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K08003
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Nagasawa Shinsuke 京都府立医科大学, 医学(系)研究科(研究院), 助教 (80835025)
• Co-Investigator(Kenkyū-buntansha): 高橋 淳子 早稲田大学, 理工学術院(情報生産システム研究科・センター), 教授(任期付) (80415702)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: 放射線防護剤 / 放射線増感剤 / 放射線治療

Outline of Final Research Achievements

It has been demonstrated that 5-ALA possesses extremely ideal properties, having the ability to protect normal tissues from radiation and sensitize cancer tissues to radiation at clinically safe concentrations, both in vitro and in vivo. 5-ALA is a medication that can be taken orally, and it is characterized by its minimal invasiveness to the human body compared to intravenous injections. The combination of 5-ALA with radiation therapy promissies the possibility of achieving high anti-tumor effects and radiation therapy with minimal side effects.

Free Research Field

放射線治療学

Academic Significance and Societal Importance of the Research Achievements

これまで達成されなかった放射線防護能と放射線増感能の両方を有する放射線増感剤の開発という意味だけに留まらず、放射線治療の効果を高めると同時に放射線有害事象を減らせるという意味で、放射線治療の適応疾患と適応年齢（特に小児）を大きく拡げる可能性という臨床的に大きなimpactをもたらす可能性を有する。